Phenotypic screens identify biologic regulators of nanoparticle uptake in diffuse midline glioma

For children with a specific and devastating type of brain tumor called diffuse midline glioma, the path to treatment is blocked by a formidable biological wall. These tumors arise in the center of the brain, in deep structures like the pons or thalamus, making them impossible to remove with surgery. While radiation offers a brief reprieve, the disease almost always returns. Scientists have long hoped that tiny, engineered particles called nanoparticles could carry life-saving drugs directly to these tumors, bypassing the body's natural defenses. However, a fundamental mystery has stalled progress: even when these particles reach the tumor, the cancer cells often refuse to let them in. The cells act as gatekeepers, and without understanding the specific biological switches that control these gates, doctors cannot force the door open.

To solve this, researchers needed to move beyond guessing which chemical shapes might work best. Instead, they decided to ask the cancer cells themselves what controls their intake. By treating the cells like a complex machine with thousands of hidden levers, the team set out to find which levers, when pulled, would make the cells more willing to accept the nanoparticles. This approach shifts the focus from designing better particles to understanding the biology of the target, a strategy that could unlock new ways to deliver medicine to the most stubborn cancers.

In a new study, a team of scientists at institutions including the Broad Institute and Boston Children's Hospital tackled this problem using a method that treats the genome like a vast library of switches. They worked with patient-derived models of diffuse midline glioma, growing the tumor cells in the lab to create a living testbed. The researchers used a powerful genetic tool to systematically turn off, one by one, thousands of different genes in these cells. They were looking for a specific outcome: which cells, after having a specific gene disabled, suddenly became much better at swallowing the nanoparticles? To test this, they introduced fluorescent nanoparticles into the cells. These particles glowed under a microscope, allowing the scientists to sort the cells into two groups: those that had taken in a lot of the glowing cargo and those that had taken in very little.

By comparing the genetic makeup of the "high uptake" cells against the "low uptake" cells, the team could identify exactly which genes were responsible for blocking the nanoparticles. The screen revealed a surprising leader in this biological blockade: a protein called beta-catenin. In the cells where the gene for beta-catenin was turned off, the nanoparticles flooded in. This finding was significant because beta-catenin is well known for its role in holding cells together and sending growth signals, but its role as a gatekeeper for drug delivery had never been explored. The researchers confirmed this result in two different patient models and found that removing beta-catenin made the cells more receptive to nanoparticles regardless of the particle's surface coating or whether it was made of fat or plastic.

To understand why this happened, the scientists looked deeper into the changes occurring inside the cells when beta-catenin was removed. They discovered that the loss of this protein triggered a chain reaction that softened the cell's outer shell. Using a specialized microfluidic device that measures how stiff a single cell is, they found that the beta-catenin-deficient cells were significantly less rigid than normal cells. This softening was accompanied by a shift in how the cells ate. Normally, these tumor cells rely on a process called macropinocytosis, where they gulp down large amounts of fluid and debris. When beta-catenin was removed, this gulping mechanism slowed down, and the cells switched to a more selective method called receptor-mediated endocytosis, where they grab specific items from their environment. This change in behavior made the cells more efficient at pulling in the nanoparticles.

The study did not stop at identifying a single protein. The genetic screen also highlighted several other pathways that regulate how cells interact with nanoparticles, particularly those involving the MAPK and mTOR signaling networks. These are communication systems inside the cell that are often overactive in cancer. The researchers tested whether they could mimic the effect of turning off beta-catenin by using existing drugs that block these signaling pathways. They treated the tumor cells with a drug called trametinib, which inhibits the MAPK pathway. The result was the same as the genetic experiment: the drug-treated cells took up significantly more nanoparticles. This suggests that doctors might be able to use existing cancer medications not just to kill tumor cells, but to "prime" them, making them more open to receiving drug-carrying nanoparticles.

The findings offer a new blueprint for treating these difficult brain tumors. Rather than endlessly tweaking the chemical design of the nanoparticles to see what sticks, the research suggests a biology-first approach. By understanding the specific regulators that control cell entry, scientists can identify ways to temporarily alter the cell's state to improve delivery. The study demonstrates that a combination of genetic screening and pharmacological intervention can reveal hidden vulnerabilities in cancer cells. While the work was conducted in the lab, it points toward a future where treatment strategies are tailored to the specific biological landscape of a patient's tumor, potentially turning a barrier into a doorway for life-saving therapies.